Back to results
RecruitingPhase 1

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study

NCT06770296

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Jiangsu Provincial People's Hospital

Nanjing, Jiangsu, China

Contact

Yongmei Yin, Ph.D

025-68307102ymyin@njmu.edu.cn
View on ClinicalTrials.gov
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study — TrialFind